Ranitidine recall – Sandoz Inc.

October 30, 2019

On September 23, 2019, Sandoz, Inc. announced issued a voluntary recall of all lots of Ranitidine capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will mail letters to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Product NameNDC NumberLot Nbr.Expiration DateDate of Manufacture
RANITIDINE 150mg Capsules 500 count0781-2855-05HD186204/30/202004/19/2017
RANITIDINE 150mg Capsules 500 count0781-2855-05HP943809/30/202009/05/2017
RANITIDINE 150mg Capsules 500 count0781-2855-05HP943909/30/202009/06/2017
RANITIDINE 150mg Capsules 500 count0781-2855-05HP944009/30/202009/05/2017
RANITIDINE 150mg Capsules 60 count0781-2855-60HC926604/30/202004/19/2017
RANITIDINE 150mg Capsules 60 count0781-2855-60HD186504/30/202004/19/2017
RANITIDINE 150mg Capsules 60 count0781-2855-60HP944109/30/202009/06/2017
RANITIDINE 150mg Capsules 60 count0781-2855-60JK799408/31/202108/07/2018
RANITIDINE 150mg Capsules 60 count0781-2855-60JK865908/31/202108/07/2018
RANITIDINE 300mg Capsules 30 count0781-2865-31HD862504/30/202004/27/2017
RANITIDINE 300mg Capsules 30 count0781-2865-31HD927504/30/202004/27/2017
RANITIDINE 300mg Capsules 30 count0781-2865-31HU220708/31/202008/24/2017
RANITIDINE 300mg Capsules 30 count0781-2865-31HX667603/31/202103/20/2018
RANITIDINE 300mg Capsules 30 count0781-2865-31HX667703/31/202103/20/2018

Additional information is available on the FDA’s website:


Last updated: March 13, 2020

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.